Olr1064 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the Olr1064 protein, which is an olfactory receptor within the G-protein-coupled receptor (GPCR) superfamily. These receptors, including Olr1064, play a crucial role in the detection of odorant molecules and are integral to the process of olfactory perception. Olr1064 is expressed in the membranes of olfactory sensory neurons located in the nasal epithelium, where it interacts with specific odorant molecules from the environment. Upon binding an odorant, Olr1064 undergoes a conformational change that activates an intracellular signaling cascade mediated by G-proteins. This cascade ultimately leads to the generation of an electrical signal that is transmitted to the brain, where it is interpreted as a distinct odor. Inhibitors of Olr1064 are small molecules designed to bind to the receptor's odorant-binding site or other critical regions, preventing the receptor from interacting with its natural ligands. By blocking this interaction, these inhibitors effectively disrupt the receptor's ability to initiate the olfactory signal transduction process, thereby modulating the perception of specific smells associated with Olr1064.
The development of Olr1064 inhibitors involves a deep understanding of the receptor's structural biology and the molecular interactions that are crucial for its function. Researchers typically utilize high-throughput screening techniques to identify initial lead compounds that demonstrate potential inhibitory effects on Olr1064. These lead compounds are then optimized through structure-activity relationship (SAR) studies, where their chemical structures are refined to enhance binding affinity, specificity, and stability within the receptor's binding pocket. The chemical structures of Olr1064 inhibitors are diverse, often incorporating functional groups that enable strong interactions with the receptor, such as hydrogen bonds, hydrophobic interactions, and van der Waals forces. Advanced structural biology techniques, including X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to visualize these interactions at an atomic level, providing critical insights that guide the design and refinement of these inhibitors. Achieving high selectivity is a key objective in the development of Olr1064 inhibitors, ensuring that these compounds specifically target Olr1064 without affecting other olfactory receptors or GPCRs with similar structural features. This selectivity is essential for enabling precise modulation of Olr1064 activity, allowing researchers to explore its specific role in olfactory perception and to gain a deeper understanding of the molecular mechanisms underlying the sense of smell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
mTOR inhibitor, potentially affecting cell growth and proliferation pathways, influencing Olr1064 activity. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
BRAF inhibitor, might modulate the MAPK/ERK pathway, thereby influencing Olr1064. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK inhibitor, can affect MAPK/ERK signaling, potentially influencing Olr1064's activity. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
BCR-ABL/Src kinase inhibitor, could disrupt cell proliferation and survival pathways affecting Olr1064. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor, potentially influencing cytokine signaling pathways affecting Olr1064. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
BRAF inhibitor, might alter MAPK/ERK signaling pathways, impacting Olr1064. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $391.00 $597.00 $755.00 $1192.00 $5000.00 $9370.00 | 2 | |
PI3K inhibitor, can affect cell survival and proliferation pathways influencing Olr1064. | ||||||
BAY 80-6946 | 1032568-63-0 | sc-503264 | 5 mg | $562.00 | ||
PI3K inhibitor, potentially impacting signaling pathways relevant to Olr1064's function. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
MEK inhibitor, might modulate cell differentiation and proliferation signals related to Olr1064. | ||||||